Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study

被引:23
作者
Alexander, Jacob [1 ]
Tung, Bruce Y. [1 ]
Croghan, Anne [1 ]
Kowdley, Kris V. [1 ]
机构
[1] Univ Washington, Med Ctr, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA
关键词
8-isoprostane; hyaluronic acid; iron depletion; phlebotomy; procollagen III peptide; YKL-40;
D O I
10.1111/j.1478-3231.2007.01449.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Hepatic iron deposition has been associated with decreased response to interferon-alpha monotherapy, and has been speculated to contribute to disease progression in chronic hepatitis C (CHC). We performed this study to evaluate the effect of iron depletion on biochemical and virologic markers, and markers of lipid peroxidation and fibrogenesis. Materials and Methods: Eighteen patients with CHC who did not have a virologic response to interferon monotherapy underwent weekly phlebotomies until iron depletion (serum ferritin < 50 ng/ml). Serum levels of alanine transaminase (ALT), hepatitis C virus-RNA, transferrin saturation, ferritin, 8-isoprostane, hylauronic acid, amino-terminal procollagen III peptide and YKL-40 were measured before and after iron depletion. Results: There was a statistically significant reduction of serum ALT, transferrin saturation and serum ferritin after iron depletion (range 4-11 phlebotomies). Serum ALT returned to normal after iron depletion in four (22%) patients. There was a significant reduction in serum procollagen III peptide level among patients who achieved biochemical response. No significant reduction was noted in serum levels of other markers. Conclusions: Iron depletion was associated with a biochemical response in 22% of patients who did not respond to interferon monotherapy. There was a significant reduction in a key marker of fibrogenesis among patients with biochemical response. These data support longer-term studies of iron depletion in CHC.
引用
收藏
页码:268 / 273
页数:6
相关论文
共 37 条
[1]   Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment [J].
Boucher, E ;
Bourienne, A ;
Adams, P ;
Turlin, B ;
Brissot, P ;
Deugnier, Y .
GUT, 1997, 41 (01) :115-120
[2]  
Carlo C, 2003, HEPATO-GASTROENTEROL, V50, P1467
[3]   Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review [J].
Coon, JT ;
Ernst, E .
JOURNAL OF HEPATOLOGY, 2004, 40 (03) :491-500
[4]   Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial [J].
Di Bisceglie, AM ;
Bonkovsky, HL ;
Chopra, S ;
Flamm, S ;
Reddy, RK ;
Grace, N ;
Killenberg, P ;
Hunt, C ;
Tamburro, C ;
Tavill, AS ;
Ferguson, R ;
Krawitt, E ;
Banner, B ;
Bacon, BR .
HEPATOLOGY, 2000, 32 (01) :135-138
[5]   MEASUREMENTS OF IRON STATUS IN PATIENTS WITH CHRONIC HEPATITIS [J].
DIBISCEGLIE, AM ;
AXIOTIS, CA ;
HOOFNAGLE, JH ;
BACON, BR .
GASTROENTEROLOGY, 1992, 102 (06) :2108-2113
[6]  
Fargion S, 2002, AM J GASTROENTEROL, V97, P1204
[7]   A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C [J].
Fong, TL ;
Han, SH ;
Tsai, NCS ;
Morgan, TR ;
Mizokami, M ;
Qian, DJ ;
Phan, C ;
Goad, K ;
Redeker, AG .
JOURNAL OF HEPATOLOGY, 1998, 28 (03) :369-374
[8]   Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial [J].
Fontana, RJ ;
Israel, J ;
LeClair, P ;
Banner, BF ;
Tortorelli, K ;
Grace, N ;
Levine, RA ;
Fiarman, G ;
Thiim, M ;
Tavill, AS ;
Bonkovsky, HL .
HEPATOLOGY, 2000, 31 (03) :730-736
[9]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[10]  
Guyader D, 1999, AM J GASTROENTEROL, V94, P1696, DOI 10.1111/j.1572-0241.1999.01170.x